Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
